Clinical Trial Update: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 study of YIV-906 in combination with Sorafenib for HBV-positive hepatocellular carcinoma has completed. It investigates the use of YIV-906 (formerly PHY…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• YIV-906 (PHY906)

Snippet

Sponsor: Yiviva Inc. | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED